3,5-dimethoxy-4'-aminomethyl-trans-stilbene | 1240471-42-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3,5-dimethoxy-4'-aminomethyl-trans-stilbene
• 英文别名: [4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenyl]methanamine
• CAS: 1240471-42-4
• 化学式: C₁₇H₁₉NO₂
• 分子量: 269.343
• InChiKey: PVEQHPRKISCJHK-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氨甲基四氢吡喃 、 3,5-dimethoxy-4'-aminomethyl-trans-stilbene 、 N,N'-羰基二咪唑 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 以54 %的产率得到(E)-1-(4-(3,5-dimethoxystyryl)benzyl)-3-((tetrahydro-2H-pyran-4-yl)methyl)urea
  参考文献：
  名称：

  发现一种新的先导化合物，其特征是二苯乙烯延伸支架作为可溶性环氧化物水解酶抑制剂来对抗脓毒症

  摘要：

  最近，一些可溶性环氧化物水解酶（sEH）抑制剂通过延长生存时间来治疗脓毒症的潜力有限，但不幸的是它们未能提高生存率。在这项研究中，我们最初鉴定了一个新的靶点，属于一种名为二苯乙烯的天然骨架，抑制小鼠 sEH 的 IC 值为 644 nM。基于天然支架的 sEH 抑制剂受到的关注较少。构效关系 (SAR) 引导的结构优化和计算机辅助骨架生长的结合产生了高效的先导化合物 (IC50: 4.0 nM)。剂量反应研究表明（腹腔注射剂量为 0.5-5 mg/kg）可通过降低肝脏中炎症因子 TNF-α 和 IL-6 的水平显着提高存活率和存活时间。有趣的是，肝脏中的蓄积量远高于血浆中的蓄积量（AUC 比率：175）。此外，在抑制人 sEH 方面，其 IC50 值 (1.5 nM) 与 EC5026 (1.7 nM) 相同。总之，天然支架延伸的 sEH 抑制剂有潜力成为解决脓毒症治疗中未满足的医疗需求的

  DOI：

  10.1016/j.ejmech.2023.116113
• 作为产物：
  描述：

  4-碘苄胺 、 1-乙烯基-3,5-二甲氧基苯 在 四丁基溴化铵 、 potassium acetate 、 palladium diacetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以50%的产率得到3,5-dimethoxy-4'-aminomethyl-trans-stilbene
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer

  摘要：

  A series of new resveratrol analogues were designed and synthesized and their inhibitory activities against aromatase were evaluated. The crystal structure of human aromatase (PDB 3eqm) was used to rationalize the mechanism of action of the aromatase inhibitor 32 (IC50 0.59 mu M) through docking, molecular mechanics energy minimization, and computer graphics molecular modeling, and the information was utilized to design several very potent inhibitors, including compounds 82 (IC50 70 nM) and 84 (IC50 36 nM). The aromatase inhibitory activities of these compounds are much more potent than that for the lead compound resveratrol, which has an IC50 of 80 mu M. In addition to aromatase inhibitory activity, compounds 32 and 44 also displayed potent QR2 inhibitory activity (IC50 1.7 mu M and 0.27 mu M, respectively) and the high-resolution X-ray structures of QR2 in complex with these two compounds provide insight into their mechanism of QR2 inhibition. The aromatase and quinone reductase inhibitors resulting from these studies have potential value in the treatment and prevention of cancer. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.05.042

文献信息

• Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer
  作者：Bin Sun、Juma Hoshino、Katie Jermihov、Laura Marler、John M. Pezzuto、Andrew D. Mesecar、Mark Cushman

  DOI：10.1016/j.bmc.2010.05.042

  日期：2010.7

  A series of new resveratrol analogues were designed and synthesized and their inhibitory activities against aromatase were evaluated. The crystal structure of human aromatase (PDB 3eqm) was used to rationalize the mechanism of action of the aromatase inhibitor 32 (IC50 0.59 mu M) through docking, molecular mechanics energy minimization, and computer graphics molecular modeling, and the information was utilized to design several very potent inhibitors, including compounds 82 (IC50 70 nM) and 84 (IC50 36 nM). The aromatase inhibitory activities of these compounds are much more potent than that for the lead compound resveratrol, which has an IC50 of 80 mu M. In addition to aromatase inhibitory activity, compounds 32 and 44 also displayed potent QR2 inhibitory activity (IC50 1.7 mu M and 0.27 mu M, respectively) and the high-resolution X-ray structures of QR2 in complex with these two compounds provide insight into their mechanism of QR2 inhibition. The aromatase and quinone reductase inhibitors resulting from these studies have potential value in the treatment and prevention of cancer. (C) 2010 Elsevier Ltd. All rights reserved.
• Discovery of a novel lead characterized by a stilbene-extended scaffold against sepsis as soluble epoxide hydrolase inhibitors
  作者：Zi-Qiang Feng、Jing Ding、Min-Zhen Zhu、Wei-Song Xie、Rui-Chen Liu、Si-Si Liu、Si-Meng Liu、Ming-Jia Yu、Xin-Hong Zhu、Jian-Hua Liang

  DOI：10.1016/j.ejmech.2023.116113

  日期：2024.2

  Recently, some inhibitors of soluble epoxide hydrolase (sEH) showed limited potential in treating sepsis by increasing survival time, but they have unfortunately failed to improve survival rates. In this study, we initially identified a new hit , belonging to a natural skeleton known as stilbene and having an IC of 644 nM on inhibiting murine sEH. Natural scaffold-based sEH inhibitors are paid less

  最近，一些可溶性环氧化物水解酶（sEH）抑制剂通过延长生存时间来治疗脓毒症的潜力有限，但不幸的是它们未能提高生存率。在这项研究中，我们最初鉴定了一个新的靶点，属于一种名为二苯乙烯的天然骨架，抑制小鼠 sEH 的 IC 值为 644 nM。基于天然支架的 sEH 抑制剂受到的关注较少。构效关系 (SAR) 引导的结构优化和计算机辅助骨架生长的结合产生了高效的先导化合物 (IC50: 4.0 nM)。剂量反应研究表明（腹腔注射剂量为 0.5-5 mg/kg）可通过降低肝脏中炎症因子 TNF-α 和 IL-6 的水平显着提高存活率和存活时间。有趣的是，肝脏中的蓄积量远高于血浆中的蓄积量（AUC 比率：175）。此外，在抑制人 sEH 方面，其 IC50 值 (1.5 nM) 与 EC5026 (1.7 nM) 相同。总之，天然支架延伸的 sEH 抑制剂有潜力成为解决脓毒症治疗中未满足的医疗需求的